Participated · Seed · Jul 2026

Accipiter Biosciences applies artificial-intelligence tools developed at the University of Washington’s Institute for Protein Design to engineer proteins capable of binding multiple cellular targets simultaneously. The company runs both partnered programs (including collaborations and license agreements with Pfizer and Kite Pharma) and internal drug-development programs, with a current focus on immunology-related conditions alongside a lead oncology program. Its Pfizer agreement included an upfront payment and the potential to earn over $330 million in milestones and royalties, and the Kite/Gilead collaboration is similarly structured. Accipiter launched in March 2023 and has grown its team to 22 employees, planning to expand to about 30 within the next six to twelve months. With the recent $10.5 million seed top-up (bringing total raised to about $23.2 million), the company intends to accelerate advancement of three to four programs into clinical trials versus its original plan of one or two.

Participated · Seed · Jun 2026

Ralo operates an AI-native mortgage brokerage that automates loan shopping, underwriting coordination and the back-office work traditionally handled by loan officers and processors. The company claims its AI systems secure rates more than half a percentage point below the national average, close mortgages in about 15 days on average, and are on average 4x less expensive than other brokers. Ralo pairs AI-powered loan officers with human support as needed, offers instant personalized rate quotes and enables pre-approval in minutes. It closed its first loans in March 2026 and reports revenue is doubling month over month. Ralo is licensed in California, Colorado and Texas and plans to expand to additional states this year. The startup was founded by former Google product manager Arjun Lalwani and former Google engineer and Goldman Sachs quant Helly Shah and is headquartered in New York City.

Participated · Seed · Nov 2025

Hearvana is pioneering a platform that delivers real-time, on-device audio augmentation and comprehension, enabling machines and people to achieve superhuman listening abilities. The technology allows AI assistants, hearing aids, smart glasses and other voice-enabled products to detect intent and context accurately even in noisy, complex environments. Founded by Professor Shyam Gollakota together with embedded-systems and audio-AI experts Malek Itani and Tuochao Chen, the team previously introduced innovations such as Target Speech Hearing, Sound Bubble, Full-Duplex Dialogue Agents and Proactive Conversational Assistants. Their deep expertise in auditory computing, embedded intelligence and deep learning underpins a product roadmap that bridges cutting-edge research with scalable real-world use cases. Hearvana plans to deploy its new capital to grow engineering and go-to-market teams and to initiate commercial pilot programs with consumer-electronics and AI-ecosystem partners. The article provided no revenue, user or other operating metrics.

Participated · Seed · Sep 2025

Founded in 2024 and headquartered in Seattle, Ethosphere develops a voice AI platform that captures live, in-store customer interactions and transforms them into aggregated, personalized guidance for frontline retail staff. By leveraging large language models, the system delivers coaching insights that help associates improve customer experience, foster loyalty, and drive brick-and-mortar sales. The company positions its technology as augmenting, not replacing, human interaction, addressing what it sees as a key gap in existing retail AI solutions. Early traction includes global retail partnerships with leading brands and pilot programs that are being scaled with new funding. Ethosphere’s human-centric approach is designed to strengthen brand-to-customer relationships while giving managers a centralized view of store-level performance. The recent $2.5 million capital infusion provides the runway to expand these pilots and refine the product for broader market adoption.

Participated · Seed · May 2025

CueZen is an AI-based personalization engine for health that seamlessly orchestrates sensor technologies with evidence-based health programs to turn data into actionable interventions. Its platform delivers personalized programs across general wellness, women’s health, metabolic health, cardiovascular care, and sleep disorders, and supports journeys, coaches, nudges, and outcomes. Organizations including Titan, NHS, and Microport use CueZen to increase enrollment, engagement, and adherence. The company notes Singapore uses its platform to evaluate and deliver personalized interventions daily to over 3 million residents for disease prevention. CueZen plans to expand enterprise partnerships and deepen platform capabilities, using new capital to grow sales and AI teams and accelerate product development. Founded in 2021, CueZen describes itself as a global health technology company focused on improving retention, engagement, and revenue opportunities for health enterprises.